ofloxacin has been researched along with Necrotizing Pyelonephritis in 36 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h [q8h]), a new carbapenem, versus those of intravenous levofloxacin (250 mg q24h) in patients with complicated urinary tract infections (cUTIs) or pyelonephritis." | 9.14 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ( Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W, 2009) |
| "Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies." | 9.14 | Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. ( Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R, 2010) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 9.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| "A double-blind, noninferiority trial was conducted to establish the safety and efficacy of a once-daily, 5-day course of levofloxacin 750 mg compared to a twice-daily, 10-day course of ciprofloxacin in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)." | 9.12 | A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. ( Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J, 2007) |
| "To evaluate, in two randomized, multicenter trials, levofloxacin compared with ciprofloxacin and lomefloxacin for efficacy and safety in treating acute pyelonephritis." | 9.08 | Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. ( Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA, 1998) |
| "The efficacy and safety of parenteral ofloxacin were evaluated in an open, multicenter study of hospitalized patients with pyelonephritis." | 9.07 | Multicenter open-label study of parenteral ofloxacin in treatment of pyelonephritis in adults. ( Cox, CE; Gentry, LO; Rodriguez-Gomez, G, 1992) |
| "The interim findings of two studies of intravenous ofloxacin for the treatment of pyelonephritis are presented." | 9.07 | Parenteral ofloxacin in treatment of pyelonephritis. ( Cox, CE, 1991) |
| "The objective of this study was to assess the in vitro activity of levofloxacin compared to other antibiotics against Escherichia coli strains isolated from female patients with acute pyelonephritis in 23 French hospitals in 2005." | 7.74 | [In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005]. ( Dib-Smahi, C; Lascols, C; Soussy, CJ, 2007) |
| "This pilot study was undertaken to characterise the pharmacokinetics, pharmacodynamics and potential clinical efficacy of levofloxacin 750 mg once daily for 5 days for treatment of women with acute uncomplicated pyelonephritis." | 7.74 | Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ( Bryski, L; Duckworth, H; Harding, G; Nicolle, L; Sitar, D; Zhanel, G, 2008) |
| " In a murine model of hematogenous pyelonephritis, the in vivo efficacies of levofloxacin and ciprofloxacin were evaluated against two methicillin-susceptible and two methicillin-resistant S." | 7.69 | In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. ( Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996) |
| "Two quinolones, fleroxacin and ofloxacin were used as oral treatment in a model of experimental pyelonephritis in rats." | 7.67 | Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis. ( Ritzerfeld, W, 1988) |
| "Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis." | 6.74 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. ( Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R, 2009) |
| "The aim of this study was to investigate the urinary bactericidal titers (UBTs) and 24-h area under the UBT-versus-time curve (AUBT) of intravenous doripenem (500 mg every 8 h [q8h]), a new carbapenem, versus those of intravenous levofloxacin (250 mg q24h) in patients with complicated urinary tract infections (cUTIs) or pyelonephritis." | 5.14 | Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ( Naber, KG; Redman, R; Wagenlehner, C; Wagenlehner, FM; Weidner, W, 2009) |
| "To evaluate the clinical and bacterial efficacies and the safety of antofloxacin hydrochloride tablets in the treatment of acute exacerbations of chronic bronchitis (AECB) and acute pyelonephritis (AP)." | 5.14 | A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. ( Bai, C; Huang, W; Mei, C; Wang, J; Xiao, Y; Xiu, Q; Xu, N; Zheng, Q, 2010) |
| "Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies." | 5.14 | Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis. ( Damiao, R; Davies, T; Kaniga, K; Kotey, P; Naber, KG; Redman, R, 2010) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 5.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| "A double-blind, noninferiority trial was conducted to establish the safety and efficacy of a once-daily, 5-day course of levofloxacin 750 mg compared to a twice-daily, 10-day course of ciprofloxacin in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)." | 5.12 | A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. ( Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J, 2007) |
| " They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day." | 5.09 | [Tavanik effectiveness and safety in the treatment of urinary tract infection complications]. ( Loran, OB; Pushkar', DIu; Rasner, PI, 2001) |
| "Fifteen patients with various forms of pyelonephritis and chronic cystitis were treated with ofloxacin." | 5.08 | [Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases]. ( Pytel', IuA; Volkova, VS, 1996) |
| "To evaluate, in two randomized, multicenter trials, levofloxacin compared with ciprofloxacin and lomefloxacin for efficacy and safety in treating acute pyelonephritis." | 5.08 | Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. ( Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA, 1998) |
| "The efficacy and safety of parenteral ofloxacin were evaluated in an open, multicenter study of hospitalized patients with pyelonephritis." | 5.07 | Multicenter open-label study of parenteral ofloxacin in treatment of pyelonephritis in adults. ( Cox, CE; Gentry, LO; Rodriguez-Gomez, G, 1992) |
| "The interim findings of two studies of intravenous ofloxacin for the treatment of pyelonephritis are presented." | 5.07 | Parenteral ofloxacin in treatment of pyelonephritis. ( Cox, CE, 1991) |
| "The objective of this study was to assess the in vitro activity of levofloxacin compared to other antibiotics against Escherichia coli strains isolated from female patients with acute pyelonephritis in 23 French hospitals in 2005." | 3.74 | [In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005]. ( Dib-Smahi, C; Lascols, C; Soussy, CJ, 2007) |
| "This pilot study was undertaken to characterise the pharmacokinetics, pharmacodynamics and potential clinical efficacy of levofloxacin 750 mg once daily for 5 days for treatment of women with acute uncomplicated pyelonephritis." | 3.74 | Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ( Bryski, L; Duckworth, H; Harding, G; Nicolle, L; Sitar, D; Zhanel, G, 2008) |
| " In a murine model of hematogenous pyelonephritis, the in vivo efficacies of levofloxacin and ciprofloxacin were evaluated against two methicillin-susceptible and two methicillin-resistant S." | 3.69 | In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. ( Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996) |
| "Two quinolones, fleroxacin and ofloxacin were used as oral treatment in a model of experimental pyelonephritis in rats." | 3.67 | Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis. ( Ritzerfeld, W, 1988) |
| "Ofloxacin, a new fluoroquinolone, was given to fifty patients (29 females and 21 males) aged 25 to 86 years with urinary tract infection or prostatitis." | 3.67 | [Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections]. ( Acar, JF; Guibert, J, 1986) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "The antibacterial activity of ofloxacin, a new gyrase inhibitor, was tested in experimental acute occlusive pyelonephritis in rats caused by Escherichia coli O4:H5 and Pseudomonas aeruginosa A 9532." | 3.67 | [Results of ofloxacin treatment of experimental urinary tract infections]. ( Ritzerfeld, W, 1986) |
| "Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis." | 2.74 | Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. ( Hedrich, D; Kaniga, K; Kotey, P; Llorens, L; Naber, KG; Redman, R, 2009) |
| "Ofloxacin was used in the empirical and etiotropic therapy of patients with severe urinary tract infection." | 2.68 | [Outlook and experience in using ofloxacin in urology]. ( Derevianko, II; Kotliarova, GA; Siniukhin, VN, 1996) |
| "Bacteremia was associated in 44% of uncomplicated and 8% of APN at risk of complications." | 1.40 | Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors. ( Caron, F; Choplin-Renard, J; Etienne, M; Pestel-Caron, M; Van Elslande, H, 2014) |
| "Pyelonephritis is rarely considered in the differential diagnosis of acute kidney injury." | 1.37 | Acute kidney injury from pyelonephritis in an elderly man: case report. ( Alroumoh, M; El-Kass, G; Galler, M; Husain, S; Mohan, P; Seshan, SV, 2011) |
| "We present the case of a patient with ADPKD and suspected cyst infection caused by group B streptococcus who was treated successfully with levofloxacin and ampicillin." | 1.33 | Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease. ( Hiyama, L; Miller, LG; Tang, A, 2006) |
| "Treatment with ofloxacin in 15 patients with chronic renal failure at different stages is reported with respect to patients undergoing hemodialysis treatment." | 1.27 | [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results]. ( Dörfler, A; Schulz, W, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 7 (19.44) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 7 (19.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Etienne, M | 1 |
| Van Elslande, H | 1 |
| Choplin-Renard, J | 1 |
| Pestel-Caron, M | 1 |
| Caron, F | 1 |
| Bedoin, M | 1 |
| Cazorla, C | 1 |
| Lucht, F | 1 |
| Berthelot, P | 1 |
| Boyer, M | 1 |
| Carricajo, A | 1 |
| Guérin, T | 1 |
| Viallon, A | 1 |
| Talan, DA | 1 |
| Krishnadasan, A | 1 |
| Abrahamian, FM | 1 |
| Stamm, WE | 1 |
| Moran, GJ | 1 |
| Wagenlehner, FM | 1 |
| Wagenlehner, C | 1 |
| Redman, R | 3 |
| Weidner, W | 1 |
| Naber, KG | 3 |
| Davila, G | 1 |
| Ruiz-Hornillos, J | 1 |
| Rojas, P | 1 |
| De Castro, F | 1 |
| Zubeldia, JM | 1 |
| Llorens, L | 1 |
| Kaniga, K | 2 |
| Kotey, P | 2 |
| Hedrich, D | 1 |
| Mirone, V | 1 |
| Wang, J | 1 |
| Xiao, Y | 1 |
| Huang, W | 1 |
| Xu, N | 1 |
| Bai, C | 1 |
| Xiu, Q | 1 |
| Mei, C | 1 |
| Zheng, Q | 1 |
| Rafat, C | 1 |
| Vimont, S | 1 |
| Ancel, PY | 1 |
| Xu-Dubois, YC | 1 |
| Mesnard, L | 1 |
| Ouali, N | 1 |
| Denis, M | 1 |
| Vandewalle, A | 1 |
| Rondeau, E | 1 |
| Hertig, A | 1 |
| Damiao, R | 1 |
| Davies, T | 1 |
| Tsuruoka, S | 1 |
| Yokota, N | 1 |
| Hayasaka, T | 1 |
| Saito, T | 1 |
| Yamagata, K | 1 |
| Husain, S | 1 |
| Alroumoh, M | 1 |
| Mohan, P | 1 |
| El-Kass, G | 1 |
| Seshan, SV | 1 |
| Galler, M | 1 |
| Tash, K | 1 |
| Serra, AL | 1 |
| Klein, M | 1 |
| Nitsch, D | 1 |
| Dürr, D | 1 |
| Wermuth, B | 1 |
| Frey, FJ | 1 |
| Hiyama, L | 1 |
| Tang, A | 1 |
| Miller, LG | 1 |
| Klausner, HA | 1 |
| Brown, P | 1 |
| Peterson, J | 3 |
| Kaul, S | 3 |
| Khashab, M | 3 |
| Fisher, AC | 2 |
| Kahn, JB | 3 |
| Soussy, CJ | 1 |
| Lascols, C | 1 |
| Dib-Smahi, C | 1 |
| Fisher, A | 1 |
| Nicolle, L | 1 |
| Duckworth, H | 1 |
| Sitar, D | 1 |
| Bryski, L | 1 |
| Harding, G | 1 |
| Zhanel, G | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Frosco, MB | 1 |
| Melton, JL | 1 |
| Stewart, FP | 1 |
| Kulwich, BA | 1 |
| Licata, L | 1 |
| Barrett, JF | 1 |
| Pytel', IuA | 1 |
| Volkova, VS | 1 |
| Derevianko, II | 1 |
| Kotliarova, GA | 1 |
| Siniukhin, VN | 1 |
| Richard, GA | 1 |
| Klimberg, IN | 1 |
| Fowler, CL | 1 |
| Callery-D'Amico, S | 1 |
| Kim, SS | 1 |
| Fujita, K | 1 |
| Mizuno, T | 1 |
| Ushiyama, T | 1 |
| Suzuki, K | 1 |
| Hadano, S | 1 |
| Satoh, S | 1 |
| Kambayashi, T | 1 |
| Mugiya, S | 1 |
| Nakano, M | 1 |
| Revelo, MP | 1 |
| Paueksakon, P | 1 |
| Goral, S | 1 |
| Helderman, H | 1 |
| Fogo, AB | 1 |
| Loran, OB | 1 |
| Pushkar', DIu | 1 |
| Rasner, PI | 1 |
| Cox, CE | 2 |
| Gentry, LO | 1 |
| Rodriguez-Gomez, G | 1 |
| Ritzerfeld, W | 2 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Schulz, W | 1 |
| Dörfler, A | 1 |
| Guerra, L | 1 |
| Erani, E | 1 |
| Xerri, L | 1 |
| Guibert, J | 1 |
| Acar, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis[NCT00229021] | Phase 3 | 741 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis[NCT00210990] | Phase 3 | 403 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis[NCT00210886] | Phase 3 | 1,109 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ofloxacin and Necrotizing Pyelonephritis
| Article | Year |
|---|---|
[From cystitis to bacterial prostatitis: experience with levofloxacin].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cystitis; Double-Blind Method; Drug Therapy, Combinatio | 2009 |
14 trials available for ofloxacin and Necrotizing Pyelonephritis
| Article | Year |
|---|---|
Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Doripenem; Double-Blin | 2009 |
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Carbapenems; Doripenem; Double-Blind Method; Fema | 2009 |
A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; Demography; Double-Blind Met | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
Topics: Aged; Anti-Infective Agents, Urinary; Carbapenems; Doripenem; Double-Blind Method; Female; Genotype; | 2010 |
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administ | 2007 |
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprof | 2007 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
[Comprehensive treatment with ofloxacin in pyo-inflammatory urologic diseases].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents, Urinary; Anti-Inflammatory | 1996 |
[Outlook and experience in using ofloxacin in urology].
Topics: Administration, Oral; Anti-Infective Agents, Urinary; Drug Administration Schedule; Forecasting; Gra | 1996 |
Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Fem | 1998 |
Complicating risk factors for pyelonephritis after extracorporeal shock wave lithotripsy.
Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Infective Agents, Urinary; Bacteriuria; Humans; Kidn | 2000 |
[Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Middle Aged; Of | 2001 |
Multicenter open-label study of parenteral ofloxacin in treatment of pyelonephritis in adults.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; | 1992 |
Parenteral ofloxacin in treatment of pyelonephritis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ceftazidime; Female; Humans; Infusions, Parent | 1991 |
21 other studies available for ofloxacin and Necrotizing Pyelonephritis
| Article | Year |
|---|---|
Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Catchment Area, Heal | 2014 |
Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Catchment Area, Health; Cohort St | 2014 |
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, | 2008 |
Toxic epidermal necrolysis induced by levofloxacin.
Topics: Fatal Outcome; Female; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pyelonephritis; Stevens-Johnson | 2009 |
Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Dru | 2011 |
Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Half-Life; Humans; Levofloxacin; Middle Aged; Ofl | 2011 |
Acute kidney injury from pyelonephritis in an elderly man: case report.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Diagnosis, Differential; | 2011 |
Rahnella aquatilis bacteremia from a suspected urinary source.
Topics: Aged; Anti-Bacterial Agents; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Lev | 2005 |
A puzzling case of high serum creatinine in a healthy woman.
Topics: Adult; Anti-Bacterial Agents; Creatinine; Drug Administration Schedule; False Positive Reactions; Fe | 2006 |
Levofloxacin penetration into a renal cyst in a patient with autosomal dominant polycystic kidney disease.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Biological Availability; Drug Therapy, Combination; Female | 2006 |
[In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005].
Topics: Acute Disease; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; France; Humans; | 2007 |
Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Escherichia coli Infections; F | 2008 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Female; Kidne | 1996 |
A 14-year-old boy with kidney allograft failure in the first month after transplantation.
Topics: Acute Disease; Adolescent; Anti-Infective Agents, Urinary; Biopsy; Creatinine; Diagnosis, Differenti | 2000 |
Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Fleroxacin; Half-Life; Klebsiella; | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |
[Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
Topics: Adult; Aged; Aluminum Hydroxide; Anti-Infective Agents, Urinary; Bacteria; Bacterial Infections; Cre | 1986 |
Ofloxacin: therapeutic activity in experimental infections.
Topics: Administration, Oral; Agranulocytosis; Animals; Anti-Infective Agents; Female; Male; Mice; Ofloxacin | 1986 |
[Results of ofloxacin treatment of experimental urinary tract infections].
Topics: Animals; Anti-Infective Agents, Urinary; Dose-Response Relationship, Drug; Escherichia coli Infectio | 1986 |
[Ofloxacin (RU 43280): clinical evaluation in urinary and prostatic infections].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cystitis; Female; Humans; Male; Middle Age | 1986 |